share_log

和鉑醫藥-B：自願公告 - 與BOOSTIMMUNE, INC. 訂立抗體偶聯藥物發現合作協議

HBM HOLDINGS-B: VOLUNTARY ANNOUNCEMENT - ENTERING INTO ANTIBODY-DRUG CONJUGATE DISCOVERY COLLABORATION AGREEMENT WITH BOOSTIMMUNE, INC.

香港交易所 ·  Feb 26 19:06
Summary by Moomoo AI
和鉑醫藥-B（02142.HK）近日宣布其全資子公司諾納生物（蘇州）有限公司已與美國生物技術公司Boostimmune, Inc.簽訂一項抗體偶聯藥物（ADC）發現合作協議。此協議旨在建立雙方在ADC療法開發上的戰略夥伴關係，諾納生物將提供其Harbour Mice®平台以開發針對新型靶點的ADC療法。Harbour Mice®平台是和鉑醫藥在創新生物藥物發現領域的專有技術，能夠生成全人源單克隆抗體，並已在免疫細胞銜接器（HBICE®）的開發上展現潛力。Boostimmune專注於開發用於腫瘤治療的創新抗體療法。和鉑醫藥表示，此次合作是集團全球戰略擴展的里程碑，並能夠產生差異化治療分子，惠及全球患者。然而，公司也提醒股東及潛在投資者注意，無法保證將能成功開發或銷售協議項下的產品，投資者應謹慎行事。該合作協議於2024年2月27日由和鉑醫藥主席及執行董事王勁松博士宣布。
和鉑醫藥-B（02142.HK）近日宣布其全資子公司諾納生物（蘇州）有限公司已與美國生物技術公司Boostimmune, Inc.簽訂一項抗體偶聯藥物（ADC）發現合作協議。此協議旨在建立雙方在ADC療法開發上的戰略夥伴關係，諾納生物將提供其Harbour Mice®平台以開發針對新型靶點的ADC療法。Harbour Mice®平台是和鉑醫藥在創新生物藥物發現領域的專有技術，能夠生成全人源單克隆抗體，並已在免疫細胞銜接器（HBICE®）的開發上展現潛力。Boostimmune專注於開發用於腫瘤治療的創新抗體療法。和鉑醫藥表示，此次合作是集團全球戰略擴展的里程碑，並能夠產生差異化治療分子，惠及全球患者。然而，公司也提醒股東及潛在投資者注意，無法保證將能成功開發或銷售協議項下的產品，投資者應謹慎行事。該合作協議於2024年2月27日由和鉑醫藥主席及執行董事王勁松博士宣布。
And Platinum Pharmaceutical-B (02142.HK) recently announced that its wholly-owned subsidiary Nona Biologics (Suzhou) Limited has signed a collaboration agreement with U.S. biotech company Boostimmune, Inc. The agreement aims to establish a strategic partnership between the two parties in the development of ADC therapeutics, and Nona Biology will provide its Harbour Mice® platform to develop ADC therapeutics for novel targets. The Harbour Mice® platform is a proprietary technology with Platinum Pharmaceuticals in the field of innovative biopharmaceutical discovery, capable of generating fully human monoclonal antibodies and has shown potential in the development of the Immune Cell Adaptor (HBICE®). Boostimmune focuses on developing innovative antibody therapies for the treatment of tumors. AND PLATINUM PHARMACEUTICALS SAID THE PARTNERSHIP IS A...Show More
And Platinum Pharmaceutical-B (02142.HK) recently announced that its wholly-owned subsidiary Nona Biologics (Suzhou) Limited has signed a collaboration agreement with U.S. biotech company Boostimmune, Inc. The agreement aims to establish a strategic partnership between the two parties in the development of ADC therapeutics, and Nona Biology will provide its Harbour Mice® platform to develop ADC therapeutics for novel targets. The Harbour Mice® platform is a proprietary technology with Platinum Pharmaceuticals in the field of innovative biopharmaceutical discovery, capable of generating fully human monoclonal antibodies and has shown potential in the development of the Immune Cell Adaptor (HBICE®). Boostimmune focuses on developing innovative antibody therapies for the treatment of tumors. AND PLATINUM PHARMACEUTICALS SAID THE PARTNERSHIP IS A MILESTONE IN THE GROUP'S STRATEGIC GLOBAL EXPANSION AND HAS THE POTENTIAL TO DELIVER DIFFERENTIATED THERAPEUTIC MOLECULES THAT BENEFIT PATIENTS WORLDWIDE. However, the Company also reminds shareholders and potential investors to note that products under the agreement cannot be guaranteed to be successfully developed or sold, and investors should exercise caution. The Cooperation Agreement was announced on 27 February 2024 by Dr. Wang Jinsong, Chairman and Executive Director of Wai Platinum Pharmaceuticals.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more